CoChat

Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases

Open access
Ratha, Sachitra K., Renuka, Nirmal, Rawat, Ismail, Bux, Faizal · 2021 · Nutrition
Cited by 70

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nut.2020.111089

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. Liu, 2020, Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases, ACS Cent Sci, 6, 315, 10.1021/acscentsci.0c00272 · DOI · Paper page
  2. Wadman, 2020, A rampage through the body, Science, 368, 356, 10.1126/science.368.6489.356 · doi:10.1126/science.368.6489.356
  3. Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 10.1016/j.cell.2020.02.052 · DOI · Paper page
  4. Thanh Le, 2020, The COVID-19 vaccine development landscape, Nat Rev Drug Discov, 19, 305, 10.1038/d41573-020-00073-5 · DOI · Paper page
  5. McCarty, 2020, Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus, Prog Cardiovasc Dis, 63, 383, 10.1016/j.pcad.2020.02.007 · DOI · Paper page
  6. Muscogiuri, 2020, Nutritional recommendations for COVID-19 quarantine, Eur J Clin Nutr, 74, 850, 10.1038/s41430-020-0635-2 · DOI · Paper page
  7. Caccialanza, 2020, Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol, Nutrition, 74, 10.1016/j.nut.2020.110835 · DOI · Paper page
  8. Laviano, 2020, Nutrition support in the time of SARS-CoV-2 (COVID-19), Nutrition, 74, 10.1016/j.nut.2020.110834 · DOI · Paper page
  9. Brown, 2014, Seaweed and human health, Nutr Rev, 72, 205, 10.1111/nure.12091 · DOI · Paper page
  10. Cicero, 2017, Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel, Nutr Rev, 75, 731, 10.1093/nutrit/nux047 · DOI · Paper page
  11. Gupta, 2013, New insights into the biodiversity and applications of cyanobacteria (blue-green algae)—Prospects and challenges, Algal Res, 2, 79, 10.1016/j.algal.2013.01.006 · DOI · Paper page
  12. Mogany, 2019, Extraction and characterisation of analytical grade C-phycocyanin from Euhalothece sp, J Appl Phycol, 31, 1661, 10.1007/s10811-018-1661-5 · DOI
  13. Chei, 2020, Spirulina maxima extract prevents activation of the NLRP3 inflammasome by inhibiting ERK signaling, Sci Rep, 10, 2075, 10.1038/s41598-020-58896-6 · DOI · Paper page
  14. Furukawa, 2008, Preventive or therapeutic composition for viral infectious disease, Google Patents;
  15. Schaeffer, 2000, Anti-HIV activity of extracts and compounds from algae and cyanobacteria, Ecotoxicol Environ Safe, 45, 208, 10.1006/eesa.1999.1862 · DOI · Paper page
  16. Wu, 2016, The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: An overview, Arch Toxicol, 90, 1817, 10.1007/s00204-016-1744-5 · DOI · Paper page
  17. Ranga Rao, 2013, In vivo bioavailability and antioxidant activity of carotenoids from microalgal biomass — A repeated dose study, Food Res Int, 54, 711, 10.1016/j.foodres.2013.07.067 · DOI
  18. Mah, 2016, Metabolic regulation of natural killer cell IFN-γ production, Crit Rev Immunol, 36, 131, 10.1615/CritRevImmunol.2016017387 · DOI · Paper page
  19. Nishida, 2019, Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments, Medicine (Baltimore), 98, 10.1097/MD.0000000000016771 · DOI
  20. Shi, 2020, COVID-19 infection: The perspectives on immune responses, Cell Death Differ, 27, 1451, 10.1038/s41418-020-0530-3 · DOI · Paper page
  21. Zhang, 2020, COVID-19: Melatonin as a potential adjuvant treatment, Life Sci, 250, 10.1016/j.lfs.2020.117583 · DOI · Paper page
  22. Li, 2020, Coronavirus infections and immune responses, J Med Virol, 92, 424, 10.1002/jmv.25685 · DOI · Paper page
  23. Yuen, 2020, SARS-CoV-2 and COVID-19: The most important research questions, Cell Biosci, 10, 40, 10.1186/s13578-020-00404-4 · DOI · Paper page
  24. Khafaga, 2018, Spirulina ameliorates methotrexate hepatotoxicity via antioxidant, immune stimulation, and proinflammatory cytokines and apoptotic proteins modulation, Life Sci, 196, 9, 10.1016/j.lfs.2018.01.010 · DOI
  25. Kuster, 2020, SARS-CoV2: Should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J, 41, 1801, 10.1093/eurheartj/ehaa235 · DOI · Paper page
  26. Adedeji, 2013, Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms, J Virol, 87, 8017, 10.1128/JVI.00998-13 · DOI · Paper page
  27. Imai, 2010, Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis, Circ J, 74, 405, 10.1253/circj.CJ-10-0045 · DOI · Paper page
  28. Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Resp Med, 8, e21, 10.1016/S2213-2600(20)30116-8 · DOI · Paper page
  29. Rico-Mesa, 2020, Outcomes in patients with COVID-19 infection taking ACEI/ARB, Curr Cardiol Rep, 22, 31, 10.1007/s11886-020-01291-4 · DOI · Paper page
  30. Aiello, 2019, Chemical and biological characterization of spirulina protein hydrolysates: Focus on ACE and DPP-IV activities modulation, J Funct Food, 63, 10.1016/j.jff.2019.103592 · DOI · Paper page
  31. Heo, 2017, A heptameric peptide purified from Spirulina sp. gastrointestinal hydrolysate inhibits angiotensin I-converting enzyme-and angiotensin II-induced vascular dysfunction in human endothelial cells, Int J Mol Med, 39, 1072, 10.3892/ijmm.2017.2941 · DOI · Paper page
  32. Zheng, 2017, Effects of IQP, VEP and Spirulina platensis hydrolysates on the local kidney renin angiotensin system in spontaneously hypertensive rats, Mol Med Rep, 16, 8485, 10.3892/mmr.2017.7602 · DOI
  33. He, 2018, Transport of ACE inhibitory peptides Ile-Gln-Pro and Val-Glu-Pro derived from Spirulina platensis across Caco-2 monolayers, J Funct Food, 83, 2586
  34. Hayashi, 1996, A natural sulfated polysaccharide, calcium Spirulan, isolated from Spirulina platensis: In vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities, AIDS Res Hum Retrov, 12, 1463, 10.1089/aid.1996.12.1463 · DOI
  35. Qureshi, 1996, Spirulina platensis exposure enhances macrophage phagocytic function in cats, Immunopharmacol Immunotoxicol, 18, 457, 10.3109/08923979609052747 · DOI · Paper page

Cited by

See all 70

Metadata

Authors
Ratha, S. K., Renuka, N., Rawat, I., & Bux, F.
Venue
Nutrition
Publisher
Elsevier BV
Published
2021-03
Volume
83
Pages
111089
ISSN
0899-9007 (ISSN-L)
OpenAlex
W3109760714
Cited by
70
References
17
FWCI
7.70
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Durban University of Technology
  • National Research Foundation (UID 84166)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.